New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures PHILADELPHIA, Jan. 6, 2026 /PRNewswire/ -- ...
Builds on existing partnership by further leveraging the combined power of real-world data, real-world evidence and privacy-preserving record linkage technology to help solve key clinical trial ...
Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...
Avik Pal, Founder and CEO of CliniOps, a technology and data company with a patented unified platform approach to digitize clinical trials. I think the aphorism "rising tides lift all boats" is an apt ...
A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...
Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...
Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update on ...
Here are seven of ZS's strengths, according to the report: The IDC MarketScape also noted, "ZS offers a wide range of GenAI capabilities across the clinical trial value chain, including site selection ...
Management indicated they "plan to deliver multiple near-term updates that assess blood-based biomarkers of metabolic health, body composition and weight loss across multiple cohorts." Data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback